Tumor Markers in Breast Cancer;Tumormarker beim Mammakarzinom

LaboratoriumsMedizin

Volumn 25, Issue 9-10, 2001, Pages 343-352

  Untch, M ^a   Sauer, H ^b   Stieber, Petra ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

breast cancer; Brustkrebs; CA 15 3; CA 27.29; CEA; HER2; MUC 1; Tumor markers; Tumormarker

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; TUMOR MARKER;

ANTIGEN DETECTION; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; COST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0035190109     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labm.2001.25.9-10.343     Document Type: Article

References (64)

1. Blanks, RG, Moss, SM, McGrahan, CE, Quin, MJ, Babb, PJ. Effect of NHS breast cancer screening programme on mortality from breast cancer in England and Wales, 1990-1998: comparison of observed with predicted mortality. BMJ 2000;321:665-9.
2. Engel, J, Schubert-Fritschle, G, Hölzel, D. Epidemiologie. In: Manual Mammakarzinome, Hrsg.:Tumorzentrum München. W. Zuckschwerdt Verlag, München 2001: 1–8.
3. Kufe, D, Inghirami, G, Abe, M, Hayes, D, Justi-Wheeler, H, Scholm, J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
4. Hilkens, J, Buijs, F, Hilgers, J, Hageman, P, Calafat, J, Sonnenberg, A, Van der Valk, M. Monoclonal antibodies against human fat globule membranes detecting differentiation antigens of mammary glands and its tumor. Int J Cancer 1984;34:197–206.
5. Bon, GG, Kenemans, P, von Kamp, GJ, Yedema, CA, Hilgers, J. Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. J Nucl Med Allied Sci 1990;34S3:151-62.
6. Price, MR, Rye, PD, Petrakou, E, Murray, A, Brady, K, Imai, S, Haga, S, Kiyozuka, Y, Schol, D, Meuienbroek, MF, Snijdewint, FG, von Mensdorff-Pouilly, S, Verstraeten, RA, Kenemans, P, Blockzjil, A,Nilsson, K, Nilsson, O, Reddish, M, Suresh, MR, Koganty, RR, Fortier, S, Baronic, L, Berg, A, Longenecker, MB, Hilgers, J, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUCl mucin. J Tumor Biol 1998:19 (Suppl 1):1–20.
7. Bieglmayer, C, Szepesi, T, Kopp, B, Hoffmann, G, Petrik, W, Guettuoche, K, Grundler, S, Gregorits, M, Strasser, M. CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumor Biol 1991;12:138-48.
8. Dnistrian, AM, Schwartz, MK, Greenberg, EJ, Smith, CA. Schwartz, DC: Evaluation of CAM26, CAM29, CA15-3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 1991;12:1282-90.
9. Bon, GG, von Mensdorff-Pouilly, S, Kenemans, P, von Kamp, GI, Verstraeten, RA, Hilgers, J, Meijer, S, Vermorken, JB. Clinical and technical evaluation of ACS BR serum assay of MUCl gene-derived glycoprotein in breast cancer and comparison with CA 15-3 assay. Clin Chem 1997:43:585-93.
10. Dnistrian, AM, Schwartz, MK, Greenberg, EJ, Schwartz, DC. BR27.29 as a marker in breast cancer. J Tumor Marker Oncol 1995;10:91-7.
11. Dnistrian, AM, Schwartz, MK, Greenberg, EJ, Smith, CA, Schwartz, DC, Maimonis, R Evaluation of a breast cancer antigen assayed on the Ciba Coming ACS: 180 automated chemiluminescence system. J Tumor Marker Oncol 1996;11:5–10.
12. Chan, DW, Beveridge, RA, Muss, H, Fritsche, HA, Hortobagyi, G, Theriault, R, Kiang, D, Kennedy, BJ, Evelegh, M. Use of Truquant BR Radioimmunoassay for early detection of breast cancer recuirence in patients with Stage II and Stage III disease. J Clin Oncol 1997;15:2322-8.
13. Anonymous. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001:19(6):1865-78.
14. Anonymous. Arbeitsgruppe Qualitatskontrolle und Standard-isierung von Tumormarkertests im Rahmen der Hamburger Sym-posien über Tumormarker. Tumordiagn u Ther 1993;13:XIX–XXII
15. Frenette, PS, Thiriwell, MP, Trudeau, M, Thomson, DM, Joseph, L, Shuster, JS. The diagnostic value of CA 27.29, CA 15-3, mucinlike carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumor Biol 1994:15(5):247-54.
16. Rodriguez de Paterna, L, Amaiz, F, Estenoz, J, Ortuno, B, Lanzos, E. Study of serum tumor markers CEA, CA 15-3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma. Int J Biol Markers 1995; 10(1):24-9.
17. Hou, MF, Chen, YL, Tseng, TF, Lin, CM, Chen, MS, Huang, CJ. Huang, JS, Hsieb, JS, Huang, TJ, Jong, SB, Huang, YF. Evaluation of serum CA 27.29, CA 15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 1999;15(9):520-8.
18. Myers, RE, Sutheriand, DJ, Meaking, JW, Kellen, JA, Malkin, DG, Malkin, A. Carcinoembryonic Antigen in Breast Cancer. Cancer 1978;42:1520-6.
19. Tormey, D, Waalkes, T. Clinical correlation between CEA and breast cancer. Cancer 1978;42:1507-11.
20. Bezwoda, W, Derman, D, Bothwell, T, MacPhil, P, Levin, J, DeMoor, N. Significance of serum concentrations of carcinoembryonic antigen, ferritin, and calcitonin in breast cancer. Cancer 1981;48:1623-8.
21. Ballesta, AM, Molina, R, Fillela, X, Jo, J, Gimenez, N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumor Biol 1995;16(1):32–41.
22. Stieber, P, Fateh-Moghadam, A, Knedel, M. CA 15-3: Methodische Evaluierung und klinische Wertigkeit bei Brusttumoren im Vergleich mit CEA und TPA, GIT-Lab Med 1988;3:109-16.
23. Lamerz, R, Stieber, P, Fateh-Moghadam, A. Serum marker combinations in human breast cancer- a review. In vivo 1993;7:607-14.
24. Dnistrian, AM, Schwarz, MK, Greenberg, EJ, Smith, CA, Schwartz, DC. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991;200:81–94.
25. Molina, R, Zanon, G, Filella, X, Moreno, F, Jo, J, Daniels, M, Latre, ML, Giminez, N, Pahisa, J, Velaso, H. Use of serial carcinoembryonic antigen and CA15-3 assays in detecting relapse in breast cancer patients. Breast Cancer Res Treat 1995:36:41-8.
26. Jäger, W, Krämer, S, Palapelas, V, Norbert, L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand.J.Clin.Lab.Invest. 1995;55(Suppl 221):87–92.
27. Vizcarra, E, Lluch, A, Cibrian, R, Jarque, F, Alberola, V, Belloch, V, Garcia Conde, J. CA 15-3 in breast cancer and comparison with CEA and TPA:a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 1996;37(3):209-16.
28. Stieber, P, Dienemann, H, Hasholzner, U, Fabricius, PG, Scham-beck, C, Weinzierl, M. Samtleben, W, Hofmann, K, Meier, W, Fateh-Moghadam, A. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and in benign diseases. Int J Biol Markers 1994;9:82-8.
29. van Dalen, A, Heering, KJ. Barak, V, Peretz, T, Cremaschi, A, Geroni, P, et al. Treatment response in metastatic breast cancer. A multi-centre study comparing UICC criteria and tumor marker changes. Breast 1996;5:82-8.
30. Akiyama, T, Sudo, C, Ogaware, H, Toyoshima, K. Yamamoto, T. The product of the human c-erb-2-gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
31. Slamon, DJ, Clark, GM. Wong, SG, Levin, WJ. Ullrich, A, McGuire, WL. Human breast cancencorrelation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
32. Sias, PE, Kotts, CE, Vetteriein, D, Shepard, M, Wong, WL. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 1990;132(1):73–80.
33. Yu, FZ, Sugano, K, Ohkura, H, Mori, S. Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma. Rinsho Byori 1991;39(10):1087-92.
34. Payne, RC, Allard, JW, Anderson-Mauser, L. Humphreys, JD, Tenney, DY, Morris, DL. Automated assay for HER-2/neu in serum. Clin Chem 2000;46 (2): 175-82.
35. Schwartz, MK, Smith, C, Schwartz, DC, Dnistrian, A, Neiman, I. Monitoring therapy by serum HER-2/neu. Int J Biol Markers. 2000; 15(4):324-9.
36. Molina, R, Jo, J, Filella, X, Bnuix, J, Castells, A, Hague, M, Ballesta, AM, Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant a non-malignant diseases. Tumor Biol 1997;18(3): 188-96.
37. Cheung, KL, Pinder, SE, Paish, C, Sadozye, AH, Chan, SY, Evans, AJ, Blamey, RW,Robertson, JF. The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 2000;15(3):203-9.
38. Sugano, K, Ushiama, M, Fukutomi, T, Tsuda, H, Kitoh, T, Ohkura, H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89(4):329-36.
39. Kandl, H, Seymour, L. Bczvvoda, WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994:70(4):739-42.
40. Molina, R, Jo, J, Filelia, X, Zanon, G. Pahisa, J, Munox, M, Farrus, B, Latre, ML, Gimenez, N, Hage, M, Estape, J, Ballesta, AM, C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996;16(4B):2295-300.
41. Mansour, OA, Zekri, AR, Harvey, J, Teramoto, Y. el-Ahmady, O. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma; three years follow-up. Anticancer Res 1997; 17(4B):3101-6.
42. Harris, LN, Liotchcva, V, Broadwater, G, Ramirez, MJ, Maimonis, P, Anderson, S. Everett, T, Harpole, D, Moore, MB, Berry, DA, Rizzeri, D. Vredenburgh, JJ, Bentley, RC. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19(6): 1698-706.
43. Molina, R, Jo, J, Filelia, X, Zanon, G, Farms, B, Munoz, M, Latre, ML, Pahisa, J, Velasco, M, Fernandez, P, Estape, J, Ballesta, AM, C-erbB-2, CEA and CA 15-3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999;19(4A): 2551-5.
44. Gion, M. Mione, R, Nascimben, O, Valsecchi, M, Gatti, C, Leon, A, Bruscagnin, G. The Tumor associated antigen CA15-3 in primary breast cancer. Evaluation of 667 cases. BrJ Cancer 1991;63:809-13.
45. Molina, R, Jo, J, Filelia, X, Zanon, G, Pahisa, J, Munoz, M, Farrus, B, Latre, ML, Esriche, C, Estape, J, Ballesta, AM, C-erbB-2 oncoprotein, CEA and CA15-3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109-19.
46. Shering, S, Sherry, F. McDermott, E, O'Higgins, N, Duffy, MJ. Preoperative CA 15-3-concentrations predict outcome in breast cancer. Cancer 1998;83:2521-7.
47. Ebeling, FG, Schmitt, UM, Untch, M, Nagel, D, Fateh-Moghadam, A, Stieber, P, Seidel, D. Tumor markers CEA and CA 153 as prognostic factors in breast cancer: univariate and multivariate analysis. Anticancer Res 1999;19(4A):2545-50.
48. Ebeling, FG. Stieber, P, Untch, M, Nagel, D, Konecny, GE, Schmitt, UM, Fateh-Moghadam, A, Seidel, D. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer, submitted 5, 2001
49. Berruti, A. Tampellini, M, Torta, M, Buniva, T, Gorzegno, G, Dogliotti, L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994;30A:2082-4.
50. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
51. Lamerz, R. Reithmeier, A, Stieber, P, Eiermann, W, Fateh-Moghadam, A. Role of Blood Markers in the Detection of Metastases from Primary Breast Cancer. Diagn Oncol 1991;1:88.
52. Jäger, W, Merkle, E, Lang, N. Increasing serum tumor markers as decision criteria for hormone therapy of metastatic breast cancer. Tumor Biol 1994;12:60-6.
53. Krämer, S, Jäger, W, Katalinic, A, Lang, N. Eariy treatment of metastatic breast cancer patients after increase of CEA or CA 15-3 serum levels. Eur Soc Gynaecol Oncol, 10th Meeting of Gynaecol OncoL 1997;393-6.
54. Merimsky, O, Kovner, F, Inbar, M, Hareunevi, M. Rosenboim, Y, Chaitchik, S. Tamoxifen for disease-negative but MCA-positive breast cancer patients. Oncology Reports 1997;4:843-7.
55. Kovner, F, Merimsky, O, Hareuveni, M, Wigler, N. Chaitchik, S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 1994;35:80-3.
56. Nicolini, A, Anselmi, L, Michelassi, C, Carpi, A. Prolonged survival by “eariy” salvage treatment of breast cancer patients: a retrospective 6-year study. Brit J Cancer 1997;76 (8): 1106-11.
57. Stieber, P, M. Untch, D. Nagel, U. M. Schmitt, H. Sauer, G. Konecny, S. Kahlert, H. Hepp, D. Seidel, Prospective randomized intervention trial in breast cancer patients to clear the relevance of early diagnosis of recurrent disease by determination of tumor markers. J Cancer Res Clin Oncol 1998;124:R94.
58. Hayes, DF. Tumor markers for breast cancer. Hematol Oncol Clin North Am 1994;8:485–506.
59. Tondini, C, Hayes, DF, Gelman, R, Henderson, IC. Kufe, DW. Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107-112.
60. Van Dalen, A, Van der Linde, DL, Heering, KJ. How can treatment response be measured in breast cancer patients. Anticancer Res 1993;13:1901-4.
61. Robertson, JFR, Pearson, D, Price, MR, Selby, C. Blamey, RW, Howell, A: Objective measurement of therapeutic response in breast cancer using tumor markers. Br J Cancer 1991;64:757-63.
62. Robertson, JFR, Jaeger, W, Syzmendera, JJ, Selby, C, Coleman, R. Howell, A, Winstanley, J, Jonssen, PE, Bombardieri, E, Sainsbury, JRC, Gronberg, H, Kumpulainen, E, Blamey, RW on behalf of the European Group for Serum Tumor Markers in Breast Cancer: The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers. Eur J Cancer 1999;35(1):47–53.
63. Willsher, P, Beaver, J, Blarney, RW, Robertson, JH. Tissue polypeptide specific antigen (TPS) in the serum of patients with breast cancer. Anticancer Res 1995;15:1609-12.
64. Robertson, JFR, Whynes, DK, Dixon, AR. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 1995;72:174-7.